GeoVax Labs announced the expansion of its rights under its exclusive license agreement with City of Hope, COH, a world-renowned cancer research and treatment organization, to include development and commercialization rights against orthopoxviruses in addition to SARS-CoV-2. The original license agreement with COH provides GeoVax exclusive worldwide rights to key patents, including the use of COH’s proprietary synthetic MVA process, for developing COVID-19 vaccines, including GEO-CM04S1, a multi-antigenic SARS-CoV-2 investigational vaccine expressing the spike and nucleocapsid antigens of the SARS-CoV-2 virus. CM04S1 is currently being studied in two ongoing Phase 2 clinical trials. The amendment to the license announced today grants GeoVax an expanded field of use to develop vaccine products, such as CM04S1, which target the prevention, reduction, amelioration or treatment of COVID-19 to also include targeting the prevention, reduction, amelioration or treatment of diseases caused by a virus within the orthopoxvirus genus. Orthopoxviruses include Mpox, smallpox, and other viruses that cause disease in humans.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GOVX:
- GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate
- GeoVax announces presentation of preliminary data of Covid vaccine candidate
- GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress
- GeoVax Labs presents data from primate studies of Marburg vaccine candidate
- GeoVax to Participate at the World Vaccine Congress with Multiple Presentations
